JPMorgan analyst Zain Ebrahim raised the firm’s price target on Genmab (GMAB) to DKK 2,050 from DKK 1,650 and keeps a Neutral rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab announces data from two trials on epcoritamab-bysp
- Genmab announces primary data from Phase 3 EPCORE FL-1 study
- Genmab A/S Discloses Managerial Share Transactions as of December 1, 2025
- Genmab A/S: Promising Growth Prospects with Strategic Catalysts and Robust Pipeline
- Genmab A/S Updates Articles of Association for Financial Flexibility